0001070081-24-000015.txt : 20240808 0001070081-24-000015.hdr.sgml : 20240808 20240808160631 ACCESSION NUMBER: 0001070081-24-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 241188228 BUSINESS ADDRESS: STREET 1: 500 WARREN CORPORATE CENTER DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 500 WARREN CORPORATE CENTER DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 8-K 1 tmb-20240808x8k.htm 8-K
0001070081false00010700812024-08-082024-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2024

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

Delaware

    

001-35969

    

04-3416587

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

500 Warren Corporate Center Drive

    

Warren, NJ

07059

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 222-7000

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PTCT

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 8, 2024, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference into this Item 2.02.

Item 7.01. Regulation FD Disclosure.

The Company will host a conference call on August 8, 2024 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended June 30, 2024, as well as other corporate highlights and updates.

Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.

The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

    

Description

99.1

Press Release, dated August 8, 2024 issued by PTC Therapeutics, Inc.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: August 8, 2024

By:

/s/ Pierre Gravier

Name:

Pierre Gravier

Title:

Chief Financial Officer

EX-99.1 2 tmb-20240808xex99d1.htm EX-99.1

Exhibit 99.1

PTC Therapeutics Provides Corporate Update and   
Reports Second Quarter 2024 Financial Results  
  

– Continued strong revenue performance –

– NDAs for sepiapterin and Translarna™ submitted to FDA –

– Positive interim data readout from PTC518 PIVOT-HD study –

– On track to achieve remaining 2024 clinical and regulatory milestones –  

WARREN, N.J., August 8, 2024 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024.  

 

"I am proud of our team’s continued outstanding execution as we have accomplished all our objectives so far this year," said Matthew Klein, M.D., Chief Executive Officer. "We are in a strong cash position, submitted three drug approval applications to the FDA and remain on schedule to achieve the many milestones we have set for the remainder of 2024."  

Key Corporate Updates:  

Second quarter 2024 total revenue of $187 million
Second quarter 2024 revenue for the DMD franchise was $118 million
oTranslarna™ (ataluren) net product revenue was $70 million, driven by continued access for patients in existing geographies and continued geographic expansion.
oEmflaza® (deflazacort) net product revenue was $47 million, driven by new patient starts and continued brand loyalty.

Key Clinical and Regulatory Milestones:  

PTC submitted an NDA to the FDA for sepiapterin for the treatment of PKU in July 2024. Further regulatory submissions are planned for Japan and Brazil later in 2024.
PTC resubmitted the NDA for Translarna for the treatment of nmDMD in July 2024.
PTC achieved all objectives in the interim readout of the Phase 2 PIVOT-HD study of PTC518 in Huntington’s disease patients, which were disclosed in the second quarter.
PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in late 2024.
PTC expects to share topline data for the CardinALS trial of utreloxastat for the treatment of ALS in the fourth quarter of 2024.
The BLA for PTC’s gene therapy for AADC deficiency was accepted by FDA with priority review; the target regulatory action date is November 13, 2024.

Second-Quarter 2024 Financial Highlights: 

Total revenues were $186.7 million for the second quarter of 2024, compared to $213.8 million for the second quarter of 2023. 
Total revenues include net product revenue across the commercial portfolio of $133.2 million for the second quarter of 2024, compared to $174.6 million for the second quarter of 2023. Total revenues


also include royalty and manufacturing revenue of $53.5 million for the second quarter of 2024, compared to $39.2 million for the second quarter of 2023.  
Translarna net product revenues were $70.4 million for the second quarter of 2024, compared to $96.5 million for the second quarter of 2023. These results were due to the timing of bulk government orders. 
Emflaza net product revenues were $47.3 million for the second quarter of 2024, compared to $65.7 million for the second quarter of 2023. These results were driven by the expiration of Emflaza’s orphan drug exclusivity in February 2024.  
Roche reported Evrysdi 2024 year-to-date sales of approximately CHF 838 million, resulting in royalty revenue of $53.2 million to PTC for the second quarter of 2024, as compared to $36.9 million for the second quarter of 2023. 
Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $132.2 million for the second quarter of 2024, compared to $185.9 million for the second quarter of 2023. The decrease in quarterly research and development expenses reflects strategic portfolio prioritization as PTC continues to focus its resources on its differentiated, high-potential programs. Included in second quarter 2024 R&D expense is a $15.0 million regulatory success-based milestone related to the Censa acquisition.   
Non-GAAP R&D expenses were $122.7 million for the second quarter of 2024, excluding $9.4 million in non-cash, stock-based compensation expense, compared to $170.3 million for the second quarter of 2023, excluding $15.5 million in non-cash, stock-based compensation expense. 
GAAP SG&A expenses were $69.5 million for the second quarter of 2024, compared to $88.4 million for the second quarter of 2023. The decrease in quarterly selling, general and administrative expenses reflects lower employee costs due to the reduction in workforce in 2023.  
Non-GAAP SG&A expenses were $59.7 million for the second quarter of 2024, excluding $9.8 million in non-cash, stock-based compensation expense, compared to $74.6 million for the second quarter of 2023, excluding $13.8 million in non-cash, stock-based compensation expense.  
Change in the fair value of deferred and contingent consideration was a loss of $5.1 million for the second quarter of 2024, compared to a gain of $128.9 million for the second quarter of 2023. The change in fair value of contingent consideration is primarily related to the strategic portfolio prioritization and the decision to discontinue the Friedreich ataxia and Angelman syndrome gene therapy programs in the second quarter of 2023. As a result, PTC determined that the fair value for all of the contingent consideration payable related to Friedreich ataxia and Angelman syndrome was $0 and recorded a gain of $129.8 million. 
Tangible asset impairment and losses (gains) on transactions, net, was a loss of $1.8 million for the second quarter of 2024, compared to $0 million for the second quarter of 2023. These results were due to the sale of certain assets related to gene therapy manufacturing and fixed asset impairments, partially offset by a gain on lease terminations and a gain on sales of certain fixed assets. 
Net loss was $99.2 million for the second quarter of 2024, compared to net loss of $198.9 million for the second quarter of 2023. 
Cash, cash equivalents, and marketable securities was $1,093.3 million on June 30, 2024, compared to $876.7 million on December 31, 2023.  During the second quarter of 2024, PTC amended its agreement with Royalty Pharma and exercised one of its put options in exchange for $250 million in cash, less royalties received.
Shares issued and outstanding as of June 30, 2024, were 76,900,123. 

PTC Updates Full Year 2024 Financial Guidance: 

PTC anticipates total revenues for full year 2024 to be between $700 million and $750 million.


PTC anticipates GAAP R&D and SG&A expenses for full year 2024 to be between $740 million and $835 million, including expected R&D expense milestone payments of up to $65 million. 
PTC anticipates Non-GAAP R&D and SG&A expenses for full year 2024 to be between $660 million and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million. 
PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expenses. As of June 30, 2024, $35 million in milestones have been achieved, of which $15 million has been recorded as R&D operating expenses and $20 million as contingent consideration payable.   

Non-GAAP Financial Measures: 

In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.  


PTC Therapeutics, Inc. 
Consolidated Statements of Operations 
(In thousands, except share and per share data) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,  

 

Six Months Ended June 30, 

 

2024 

 

2023 

 

2024 

 

2023 

Revenues: 

 

 

 

 

 

 

 

Net product revenue 

 133,220 

 

 174,592 

 

 310,824 

 

 362,149 

Collaboration revenue 

 - 

 

 - 

 

 - 

 

 6 

Royalty revenue 

 53,183 

 

 36,853 

 

 84,337 

 

 67,684 

Manufacturing revenue 

 

 301 

 

 

 2,363 

 

 

 1,661 

 

 4,351 

Total revenues 

 186,704 

 

 213,808 

 

 396,822 

 

 434,190 

Operating expenses: 

 

 

 

 

 

 

 

Cost of product sales, excluding amortization of acquired intangible assets 

 15,527 

 

 12,731 

 

 30,267 

 

 26,875 

Amortization of acquired intangible asset 

 2,865 

 

 47,397 

 

 54,395 

 

 86,812 

Research and development (1) 

 132,169 

 

 185,874 

 

 248,298 

 

 380,998 

Selling, general and administrative (2) 

 69,500 

 

 88,449 

 

 142,772 

 

 175,363 

Change in the fair value of deferred and contingent consideration 

 5,100 

 

 (128,900) 

 

 5,000 

 

 (126,500) 

Intangible asset impairment  

 - 

 

 217,800 

 

 - 

 

 217,800 

Tangible asset impairment and losses (gains) on transactions, net 

 

 1,761 

 

 

 - 

 

 

 1,761 

 

 

 - 

Total operating expenses 

 226,922 

 

 423,351 

 

 482,493 

 

 761,348 

Loss from operations 

 (40,218) 

 

 (209,543) 

 

 (85,671) 

 

 (327,158) 

Interest expense, net 

 (43,490) 

 

 (29,415) 

 

 (84,324) 

 

 (56,745) 

Other (expense) income, net 

 (2,025) 

 

 1,479 

 

 (434) 

 

 11,434 

Loss before income tax (expense) benefit 

 (85,733) 

 

 (237,479) 

 

 (170,429) 

 

 (372,469) 

Income tax (expense) benefit  

 (13,446) 

 

 38,596 

 

 (20,326) 

 

 34,627 

Net loss attributable to common stockholders 

 (99,179) 

 

 (198,883) 

 

 (190,755) 

 

 (337,842) 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding: 

 

 

 

 

 

 

 

Basic and diluted (in shares) 

 76,725,070 

 

 74,730,433 

 

 76,610,598 

 

 74,232,624 

Net loss per share—basic and diluted (in dollars per share) 

 (1.29) 

 

 (2.66) 

 

 (2.49) 

 

 (4.55) 

 

 

 

 

 

 

 

 

(1) Research and development reconciliation 

 

 

 

 

 

 

 

GAAP research and development 

 132,169 

 

 185,874 

 

 248,298 

 

 380,998 

Less: share-based compensation expense 

 9,428 

 

 15,529 

 

 18,395 

 

 30,842 

Non-GAAP research and development 

 122,741 

 

 170,345 

 

 229,903 

 

 350,156 

 

 

 

 

 

 

 

 

(2) Selling, general and administrative reconciliation 

 

 

 

 

 

 

 

GAAP selling, general and administrative 

 69,500 

 

 88,449 

 

 142,772 

 

 175,363 

Less: share-based compensation expense 

 9,815 

 

 13,842 

 

 19,226 

 

 27,344 

Non-GAAP selling, general and administrative  

 59,685 

 

 74,607 

 

 123,546 

 

 148,019 


 

 

 

 

 

 

 

 

 

PTC Therapeutics, Inc. 
Summary Consolidated Balance Sheets 
(in thousands, except share data) 

 

 

 

 

 

 

 

 

June 30, 2024 

 

December 31, 2023 

Cash, cash equivalents and marketable securities 

 1,093,293 

 

 876,739 

Total Assets 

$ 

 1,916,355 

 

$ 

 1,895,698 

 

 

 

 

 

 

Total debt 

 284,806 

 

 284,213 

Total deferred revenue 

 

 - 

 

 

 801 

Total liability for sale of future royalties 

 

 2,084,880 

 

 

 1,814,097 

Total liabilities 

$ 

 2,896,536 

 

$ 

 2,714,253 

 

 

 

 

 

 

Total stockholders' deficit (76,900,123 and 75,708,889 common shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively) 

 (980,181) 

 

 (818,555) 

Total liabilities and stockholders' deficit 

$ 

 1,916,355 

 

$ 

 1,895,698 

 

 


PTC Therapeutics, Inc. 
Reconciliation of GAAP Milestone Payments Full Year 2024 

(in millions) 

 

 

 

 

 

 

 

 

Milestone Payments  

 

Full Year 2024 

 

(in millions) 

 

 

Projected GAAP R&D Expense Related Milestone Payments 

 65 

Projected GAAP Contingent Consideration Payable Related Milestone Payments 

 

 25 

Total Projected GAAP Milestone Payments 

$ 

 90 

 

 

PTC Therapeutics, Inc. 

Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&D and SG&A Expense 
(In millions) 

 

 

 

 

 

 

 

 

Low End of Range 

 

High End of Range 

Projected GAAP R&D and SG&A Expense 

 740 

 

 835 

Less: projected non-cash, stock-based compensation expense 

 80 

 

 80 

Projected non-GAAP R&D and SG&A expense  

 660 

 

 755 

 

 

Acronyms:

AADC: Aromatic l-Amino Acid Decarboxylase

ALS: Amyotrophic Lateral Sclerosis

BLA: Biologics License Application

CHF: Confoederatio Helvetica Francs (Swiss francs)

DMD: Duchenne Muscular Dystrophy

EMA: European Medicines Agency

FA: Friedreich Ataxia

FDA: U.S. Food and Drug Administration

GAAP: Generally Accepted Accounting Principles

HD: Huntington’s Disease

MAA: Marketing Authorization Application

NDA: New Drug Application

nmDMD: Nonsense Mutation Duchenne Muscular Dystrophy

PKU: Phenylketonuria

R&D: Research and Development

SG&A: Selling, General, and Administrative


Today's Conference Call and Webcast Reminder:

To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "PTC Updates Full Year 2024 Revenue Guidance", including with respect to (i) 2024 total revenue guidance, (ii) 2024 GAAP and non-GAAP R&D and SG&A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.


PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Medicines Agency (EMA) determines in the re-examination process that the benefit-risk balance for the conditional marketing authorization for Translarna supports renewal of such authorization, or PTC’s ability to identify other potential mechanisms by which it may provide Translarna to nmDMD patients in the EEA; PTC's ability to use the clinical data from its international drug registry study and real-world evidence concerning Translarna's benefits to support a continued marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC's ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC's interpretation of the results of clinical trials and the totality of clinical data from its trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to sepiapterin, including any regulatory submissions and potential approvals, commercialization, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under PTC’s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC's preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC's strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi, Waylivra or sepiapterin.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.


EX-101.SCH 3 tmb-20240808.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 tmb-20240808_def.xml EX-101.DEF EX-101.LAB 5 tmb-20240808_lab.xml EX-101.LAB EX-101.PRE 6 tmb-20240808_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information
Aug. 08, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Aug. 08, 2024
Entity File Number 001-35969
Entity Registrant Name PTC THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-3416587
Entity Address, Address Line One 500 Warren Corporate Center Drive
Entity Address, City or Town Warren
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07059
City Area Code 908
Local Phone Number 222-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol PTCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001070081
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tmb-20240808.xsd tmb-20240808_def.xml tmb-20240808_lab.xml tmb-20240808_pre.xml tmb-20240808x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmb-20240808x8k.htm": { "nsprefix": "ptct", "nsuri": "http://www.ptcbio.com/20240808", "dts": { "schema": { "local": [ "tmb-20240808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "definitionLink": { "local": [ "tmb-20240808_def.xml" ] }, "labelLink": { "local": [ "tmb-20240808_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20240808_pre.xml" ] }, "inline": { "local": [ "tmb-20240808x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_8_8_2024_To_8_8_2024_qBV74BmJikufAb-8ct_Y1Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20240808x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_8_8_2024_To_8_8_2024_qBV74BmJikufAb-8ct_Y1Q", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20240808x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001070081-24-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001070081-24-000015-xbrl.zip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end XML 17 tmb-20240808x8k_htm.xml IDEA: XBRL DOCUMENT 0001070081 2024-08-08 2024-08-08 0001070081 false 8-K 2024-08-08 PTC THERAPEUTICS, INC. DE 001-35969 04-3416587 500 Warren Corporate Center Drive Warren NJ 07059 908 222-7000 false false false false Common Stock, $0.001 par value per share PTCT NASDAQ false